Zoledronat Onco Labatec, 4 mg/100 ml, solution pour perfusion
7680695430011
CH-69543
Lösung
Associated product:
ZOLEDRONAT Onco Labatec 4 mg/100ml sol perf flac
1 / 2
google
Article details
- Package size
- 1x100 ml
- Selling units
- 1
- Measure
- Durchstechflasche(n)
- Galenic form
- Lösung
- Galenic group
- unbekannt
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
acidum zoledronicum
|
4.0 MG | Substance | Wirkstoff (Principe actif) |
|
acidum zoledronicum monohydricum
|
- | Substance | WIZUS |
|
mannitolum
|
- | Substance | HNIDK |
|
natrii citras dihydricus
|
- | Substance | HNIDK |
|
natrium
|
5.63 MG | Substance | HBESI |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 134.10
Specialties list
Yes
Generic
Yes
SL addition date:
01/03/2026
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 69543
- Drug name
- Zoledronat Onco Labatec, 4 mg/100 ml, solution pour perfusion
- Galenic form
- LSINF
- ATC Code
- M05BA08
- Authorization status
- Z
- Dispensing category
- B
- First authorization
- 29/01/2025
- Authorization expiration date
- 28/01/2030
- IT Number
- 07.99.0.
- Domain
- Human medicine
Package details
- Description (FR)
- ZOLEDRONAT Onco Labatec 4 mg/100ml sol perf flac
- Description (DE)
- ZOLEDRONAT Onco Labatec 4 mg/100ml Inf Lös Durchst
- Market launch
- 01/03/2026
- Narcotic (BTM)
- No
Original drug
Aclasta, Infusionslösung
GTIN: 7680573630014
CHF 254.45